Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233987 · ClinicalTrials.gov registry record · Phase 2
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT00233987 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 98 participants.
The verdict
NCT00233987, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more cancer cells are killed. Tandem (two) autologous stem cell transplants may be an effective treatment for Hodgkin's lymphoma. PURPOSE: This phase II trial is studying how well tandem stem cell transplantation works in treating patients with progressive or recurrent Hodgkin's lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG melphalan
- DRUG carmustine
- PROCEDURE autologous-autologous tandem hematopoietic stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2005-10 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233987
The ClinicalTrials.gov registry entry for NCT00233987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00233987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233987 about?
NCT00233987 is a clinical study titled "S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma". RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more ch...
What is the current status of trial NCT00233987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2005-10. Estimated completion is 2017-12.
What interventions are being tested in trial NCT00233987?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), melphalan (DRUG), carmustine (DRUG), autologous-autologous tandem hematopoietic stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00233987?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.